Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10396
Title: An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
Austin Authors: Davis, Ian D;Skrumsager, Birte K;Cebon, Jonathan S ;Nicholaou, Theo;Barlow, John W;Moller, Niels Peter Hundahl;Skak, Kresten;Lundsgaard, Dorthe;Frederiksen, Klaus Stensgaard;Thygesen, Peter;McArthur, Grant A
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Issue Date: 15-Jun-2007
Publication information: Clinical Cancer Research; 13(12): 3630-6
Abstract: Human interleukin-21 (IL-21) is a pleiotropic class I cytokine that activates CD8(+) T cells and natural killer cells. We report a phase 1 study of recombinant human IL-21 in patients with surgically incurable metastatic melanoma. The primary objective was to investigate safety and tolerability by determining dose-limiting toxicity (DLT). The secondary objectives were to identify a dose response for various biomarkers in the peripheral blood, estimate the minimum biologically effective dose, determine the pharmacokinetics of IL-21, determine if anti-IL-21 antibodies were induced during therapy, and measure effects on tumor size according to Response Evaluation Criteria in Solid Tumors.Open-label, two-arm, dose escalation trial of IL-21 administered by i.v. bolus injection at dose levels from 1 to 100 microg/kg using two parallel treatment regimens: thrice weekly for 6 weeks (3/wk) or three cycles of daily dosing for 5 days followed by 9 days of rest (5+9).Twenty-nine patients entered the study. IL-21 was generally well tolerated and no DLTs were observed at the 1, 3, and 10 microg/kg dose levels. In the 3/wk regimen, DLTs were increased in alanine aminotransferase, neutropenia, and lightheadedness with fever and rigors. DLTs in the 5+9 regimen were increased in aspartate aminotransferase and alanine aminotransferase, neutropenia, fatigue, and thrombocytopenia. The maximum tolerated dose was declared to be 30 microg/kg for both regimens. Effects on biomarkers were observed at all dose levels, including increased levels of soluble CD25 and up-regulation of perforin and granzyme B mRNA in CD8(+) cells. One partial tumor response observed after treatment with IL-21 for 2 x 6 weeks (3/wk) became complete 3 months later.IL-21 is biologically active at all dose levels administered and is generally well tolerated, and phase 2 studies have commenced using 30 microg/kg in the 5+9 regimen.
Gov't Doc #: 17575227
URI: https://ahro.austin.org.au/austinjspui/handle/1/10396
DOI: 10.1158/1078-0432.CCR-07-0410
Journal: Clinical Cancer Research
URL: https://pubmed.ncbi.nlm.nih.gov/17575227
Type: Journal Article
Subjects: Adult
Aged
Antineoplastic Agents.administration & dosage.adverse effects.pharmacokinetics
Dose-Response Relationship, Drug
Enzyme-Linked Immunosorbent Assay
Female
Granzymes.drug effects
Humans
Interleukin-2 Receptor alpha Subunit.blood.drug effects
Interleukins.administration & dosage.adverse effects.pharmacokinetics
Male
Maximum Tolerated Dose
Melanoma.drug therapy
Middle Aged
Perforin
Pore Forming Cytotoxic Proteins.drug effects
Recombinant Proteins.administration & dosage.adverse effects.pharmacokinetics
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Apr 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.